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In the course of combating infectious agents, type I
interferon (IFN) needs a timely downregulationmech-
anism to avoid detrimental overreaction. Here we
showed a mechanism for restraining type I IFN
responses, which relied on a HECT domain ubiquitin
(Ub) E3 ligase, RAUL. RAUL limited type I IFN produc-
tion by directly catalyzing lysine 48-linked polyubi-
quitination of both interferon regulatory factor 7
(IRF7) and IRF3 followed by proteasome-dependent
degradation. Suppression of RAUL by dominant-
negative RAUL or siRNA augmented both basal and
virus-inducedproductionof type I IFN,which resulted
in reduced viral replication. The Kaposi’s sarcoma-
associated herpes virus immediate-early lytic cycle
trigger protein RTA recruited this mechanism to
augment its countermeasures against the host anti-
viral response. These results unveil a previously
unrecognized ‘‘brake mechanism’’ for type I IFN that
maintains proper low amounts of type I IFN under
physiological conditions and restrains its magnitude
when the antiviral response intensifies.
INTRODUCTION
Interferon regulatory factor 7 (IRF7) and IRF3 are master tran-
scriptional factors that regulate type I interferon (IFN) gene
(IFN-a and IFN-b) induction and innate immune defenses after
virus infection (Honda et al., 2005). IRF7, the master regulator
for type I IFN, is induced by toll-like receptor 7 (TLR7) and
TLR9, whereas IRF3 is activated through TLR3 and TLR4 (Doyle
et al., 2002). These factors need to be destroyed in a timely
manner after their activation, and this task is fulfilled by the ubiq-
uitin (Ub)-proteasome system (Kodadek et al., 2006). Recent
studies indicate that both IRF7 and IRF3 proteins undergo ubiq-
uitination-mediated proteolysis: prolyl isomerase Pin1, E3 ligase
Ro52, Ub ligase (E3) RBCC protein interacting with PKC1
(RBCK1), and human immunodeficiency virus (HIV)1 accessory
proteins Vpr and Vif have been implicated indirectly for IRF3I(Barrington et al., 1998; Hemmi et al., 2004; Higgs et al., 2008;
Kawai et al., 2004; Nakagawa and Yokosawa, 2000; Okumura
et al., 2008; Saitoh et al., 2006; Yu et al., 2005; Zhang et al.,
2008), whereas the Kaposi’s sarcoma-associated virus (KSHV)
immediate-early lytic cycle trigger protein, RNA transcriptional
activator (RTA, also known as ORF50) and the rotavirus
nonstructural protein NSP1 have been shown to target IRF7 for
proteolysis (Barro and Patton, 2007; Yu et al., 2005). Yet the
endogenous Ub E3 ligase for IRF7 is still unknown (Kaisho and
Tanaka, 2008). Although Pin1 and RBCK1 have been implicated
in the ubiquitination of activated IRF3, an endogenous E3 ligase
that directly ubiquitinates IRF3 has also not been reported. The
fact that the usually low expression of short half-lived IRF7 in
normal cells can be boosted by treatment with proteasome
inhibitors (Yu et al., 2005) clearly implies that there exists a
cellular ubiquitination mechanism for controlling the abundance
of the IRF7 protein, and this remains a key missing component in
understanding regulation of the type I IFN pathway.
Ubiquitination requires the sequential actions of three
enzymes: Ub-activating enzyme (E1), Ub-conjugating enzyme
(E2), and Ub ligase (E3), and the E3 dictates which target protein
gets ubiquitinated. Different Ub chain structures tend to direct
distinctive functional consequences, which is best manifested
by lysine 48- versus lysine 63-linked Ub chains, resulting in
proteolysis or functional activation, respectively (Chen, 2005;
Hershko and Ciechanover, 1998). There are two types of E3
ligase, HECT (homologous to E6-associated protein C terminus)
domain and the really interesting new gene (RING) finger domain
E3 Ub ligases. Similar to phosphorylation, ubiquitination is
a reversible process, and this is accomplished by deubiquiti-
nases (DUBs; also known as deubiquitinating enzymes), which
remove Ub moieties from Ub-protein conjugates, leading to
reduced ubiquitination signaling (Komander et al., 2009).
The ubiquitous nature of pathogens and stress proteins are
such that if left unchecked, the host will be overwhelmed by
immune activation. Therefore, the immune system needs to
constantly create (or maintain) a balance between activation
and inhibition to avoid detrimental overreaction. Although immu-
nologists have long been focusing on activation machinery,
a picture of how immune balance is achieved is beginning to
emerge (Liew et al., 2005). The present work set out to investi-
gate the other side of the coin, the mechanisms that restrain
type I IFN responses. RAUL (RTA-associated ubiquitin ligase)mmunity 33, 863–877, December 22, 2010 ª2010 Elsevier Inc. 863
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domain E3 Ub ligase that is able to catalyze a variety of unan-
chored poly-Ub chain types in vitro and targets the putative
transcriptional factor TIP120B for proteolysis, yet its physiolog-
ical functions are largely unknown (Garcia-Gonzalo and Rosa,
2005; Wang et al., 2006; You and Pickart, 2001; You et al., 2003).
The first implication that this particular ligase might play a role
in the IFN pathway came when RAUL, together with IRF7, were
identified in our yeast two-hybrid screening as binding partners
for the Kaposi’s sarcoma-associated virus (KSHV) immediate-
early lytic cycle trigger protein, RTA. We also observed that
RTA, as a viral E3 Ub ligase, promotes direct Ub-proteasome-
dependent proteolysis of IRF7, the master regulator of type I
IFN (Yu et al., 2005). In addition, we observed that the viral E3
RTA can cooperate with cellular E3 RAUL to enhance proteolysis
of both IRF7 and IRF3. These observations, together with the fact
that IRF7 and IRF3 share structural and functional similarities as
well as phosphorylation pathways (Sharma et al., 2003), promp-
ted us to hypothesize that RAUL itself might regulate both the
IRF7 and IRF3 proteins, thus negatively regulating type I IFN.
We further hypothesized that KSHV RTA not only copies but
also recruits this cellular negative regulatory mechanism for
type I IFN to mute antiviral innate responses.
Here we showed that RAUL regulates type I IFN by targeting
both IRF7 and IRF3 for lysine 48-linked ubiquitination and prote-
olysis, which represents an important pathway in maintaining
proper low amounts of type I IFN under physiological conditions,
and for restraining its magnitude when the antiviral innate
response intensifies. We also showed that RAUL was positively
regulated by a deubiquitinating enzyme ubiquitin-specific pro-
cessing protease 7 (Usp7 also known as HAUSP) and that
KSHV RTA utilized and enhanced this mechanism to augment
its countermeasures against the host antiviral response, which
may represent a common strategy adopted by viruses to coun-
teract innate immunity.
RESULTS
RAUL Associates with IRF7 and IRF3
A necessary step for a HECT domain E3 ligase to initiate ubiqui-
tination is physical binding to its target protein. To determine
whether and how RAUL binds to either the IRF7 or IRF3 proteins
under more physiological conditions in mammalian cells, we first
used immunoprecipitation to confirm that endogenous binding
between RAUL and IRF7 or IRF3 occurred in the mouse bone
marrow dendritic cell line DC 2.4 (Figure 1A). Next, reciprocal
immunoprecipitation and immunoblot experiments indicated
that RAUL indeed interacted with IRF7 and IRF3 (but not IRF1)
in human cells after exogenous coexpression (Figures S1A
and S1B available online). Third, we verified the associations
in vitro by glutathione-S-transferase (GST) pull-down assays
and showed that both IRF7 and IRF3 interacted with RAUL
through their N-terminal regions (Figures S1C and S1D). Fourth,
further deletion analysis showed that the amino-terminal regions
of IRF7 (amino acids 103–151) (Figure S1E) and IRF3 (amino
acids 1–128) (Figure S1F) were required for mediating the inter-
action with full-length RAUL protein, and that RAUL associated
with IRF7 and IRF3 via its N-terminal region (1–655) (Figure S1G).
Fifth, we tested whether the binding is dependent upon IRF7864 Immunity 33, 863–877, December 22, 2010 ª2010 Elsevier Inc.phosphorylation status and found that all three IRF7 phos-
phorylation-deficient mutants (IRF7S483A, IRF7D477-479, and
IRF7D490A) retained their ability to bind RAUL (Figure S1H, lanes
1, 2, and 4). A similar pattern was observed with IRF3 phosphor-
ylation mutants (data not shown), indicating that the binding
between IRF7 or IRF3 and RAUL are independent of their
phosphorylation status. Finally, we examined whether RAUL
catalytic activity affects the binding and found that its catalyti-
cally inactive mutant (C1051A, designated as Myc-RAUL-M)
was unchanged in its binding ability for IRF7 (Figure S1H,
lane 3). Collectively, these results show that RAUL binds specif-
ically to both IRF7 and IRF3 both inside cultured cells and in cell-
free extracts.
RAUL Directs IRF7 and IRF3 for Proteolysis
We next sought to determine whether RAUL, like KSHV E3 RTA,
might promote IRF7 or IRF3 proteasome-dependent proteolysis.
Indeed, coexpression of wild-type (WT) RAUL but not the cata-
lytic domain point mutant of RAUL, with IRF7 or IRF3 led to
a loss of both proteins in a dose-dependent manner, which
was prevented by treatment with the proteasome inhibitor
MG132 (Figures 1B–1E). We also observed that the N-terminal
deletion mutant (RAULD132, designated as RAUL-DN in this
article) as well as its catalytically inactive mutant (Myc-RAUL-M)
functionally acted in a dominant-negative fashion to inhibit
RAUL function (data not shown). These results indicate that
RAUL mediates IRF7 and IRF3 proteolysis in a ubiquitination-
and proteasome-dependent manner. To determine whether
RAUL also regulates endogenous IRF7 and IRF3, we transfected
increasing amounts of RAUL into 293T cells, which caused
a dose-dependent loss of the endogenous IRF7 and IRF3
proteins (Figure 1F). To determine which domains of RAUL are
involved in this proteolysis, we cotransfected RAUL mutants,
which lack either the substrate binding domain (RAULD132) or
the catalytic cysteine (RAUL-M), together with IRF3 plasmids
into 293T cells. Both the substrate-binding and intact catalytic
C-terminal domains of RAUL proved to be required (Figure 1G),
suggesting that the degradation involves both specific-target
recognition and the enzymatic activity of RAUL. We also tested
whether RAUL-mediated proteolysis depends on IRF3’s phos-
phorylation status. However, Figure 1H shows that RAUL
promoted degradation of both WT IRF3 and its phosphoryla-
tion-deficient mutant (IRF3S339A) in a cotransfection system,
indicating that the proteolysis is independent of IRF3 phosphor-
ylation status. A similar pattern was observed for IRF7 phosphor-
ylation mutants (data not shown).
We also examined whether the proteolysis occurs in the
nucleus or cytoplasm. A subcellular localization experiment
showed that when expressed alone, IRF7 and IRF3 were largely
localized in the cytoplasm, but that when coexpressed with
RAUL, a large proportion of both forms of IRF7 and IRF3 could
no longer be detected (Figure 1I, lane 4). RAUL exhibited a similar
subcellular expression pattern as IRF3 and IRF7 (Figure 1I, lane
3). Therefore, RAUL is capable of regulating both the resting
(cytoplasmic) and activated (nuclear) forms of both IRF7 and
IRF3, the key transcription factors mediating innate type I IFN
responses to cell stress, and RAUL directs them for protea-
some-dependent proteolysis in a manner that is dependent on
both the substrate-binding and catalytic domains of RAUL.
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Figure 1. RAUL Directs IRF7 and IRF3 for Proteolysis
(A) Interaction between endogenous RAUL and IRF7 or IRF3. Lysates of DC 2.4 mouse bone marrow dendritic cells treated with the proteasome inhibitor MG132
were immunoprecipitated with anti-RAUL and immunoblotted with anti-IRF7 or anti-IRF3.
(B–E) RAUL, but not its catalytically inactive mutant, causes loss of IRF7 and IRF3 proteins. Flag-IRF7 or HA-IRF3 was cotransfected with Myc-RAUL or Myc-
RAUL-M (pointmutant C1051A) into 293T cells in the presence ofMG132 (0.5mMfor 12 hr). The amounts of IRF7 and IRF3 proteinswere evaluated by immunoblot.
(C and E) Dose response with increasing amounts of Myc-RAUL.
(F) Enforced RAUL expression causes loss of endogenous IRF7 and IRF3 proteins. The indicated increasing amounts of Myc-RAUL plasmid were transfected
into 293T cells, and the endogenous IRF7 or IRF3 protein were assessed by IRF7 or IRF3 immunoblotting.
(G) RAUL-mediated IRF3 proteolysis is dependent on its substrate binding and catalytic domains. WT RAUL or its substrate binding domain deletion mutant
(Myc-RAULD132, also designated as Myc-RAUL-DN) or its catalytically inactive mutant (Myc-RAUL-M) were transfected into 293T cells and endogenous
IRF3 protein was evaluated by IRF3 immunoblotting.
(H)RAUL-mediated lossof IRF3occurs independently of IRF3phosphorylation status.Myc-RAULandWT IRF3or its phosphorylation-deficientmutant IRF3S339A
were cotransfected into 293T cells, cytoplasmic and nuclear portions were isolated, and amounts of IRF3 and RAUL were determined by immunoblotting.
(I) Subcellular distribution pattern. 293T cells were transfected with Myc-RAUL together with Flag-IRF7 or HA-IRF3 plasmids. Cytoplasmic and nuclear fractions
were isolated and IRF7, IRF3, and RAUL proteins were detected by immunoblot with Flag, HA, or RAUL antibodies, respectively.
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Figure 2. RAUL Ubiquitinates IRF7 and IRF3 In Vivo and In Vitro
(A and B) RAUL mediates ubiquitination of endogenous IRF7 and IRF3. DG75 B-lymphocyte cells were electroporated with WT Myc-RAUL or its catalytically
inactive mutant (Myc-RAUL-M) plasmids in the presence of proteasome inhibitor MG115, lysates were immunoprecipitated with anti-IRF7 and IRF3, and ubiq-
uitinated forms of IRF7 and IRF3 were determined by Ub immunoblotting.
(C) RAUL is required for endogenous IRF7 ubiquitination. Mouse bone marrow dendritic cells DC 2.4 were electroporated with siRNA-RAUL or scramble siRNA
together with HA-Ub plasmid and the indicated cells were treated with MG132. The cell lysates were immunoprecipitated with anti-IRF7 followed by Ub immu-
noblotting.
(D) RAUL is required for ubiquitination of endogenous IRF7 after TLR4 activation. Mouse primary bone marrow dendritic cells were isolated (Tseng et al., 2001)
and electroporated with dominant-negative (Myc-RAUL-DN) plasmid or control vector and the indicated cells were treated with LPS (100 ng/ml for 9 hr) and pro-
teasome inhibitor MG115. Conjugated IRF7 was determined by immunoprecipitation with anti-IRF7 followed by Ub immunoblotting.
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We then investigated whether RAUL-mediated IRF7 and IRF3
proteolysis occurs through ubiquitination. Initially, we asked
whether RAUL can induce the addition of ubiquitin chains on
endogenous IRF7 and IRF3 proteins and observed that ectopic
expression of WT RAUL, but not of its catalytically inactive
mutant, produced polyubiquitinated forms of both proteins in
the human DG7 lymphoma cell line (Figures 2A and 2B). These
results indicate that RAUL overexpression induced endogenous
IRF7 and IRF3 ubiquitination. To determine whether endogenous
IRF7 undergoes ubiquitination in resting conditions, dendritic
cells DC 2.4 were electroporated with hemagglutinin (HA)-Ub
and treated with MG132. IRF7 was readily polyubiquitinated
(Figure 2C), but this was substantially reduced in the absence
of either HA-Ub or MG132. Notably, depletion of RAUL by
specific small interfering RNA (siRNA) (see below) in the same
cells abolished IRF7 ubiquitination, suggesting that IRF7
undergoes ubiquitination and proteasome-mediated degrada-
tion events, even in the absence of pathogen induction stresses,
in which RAUL appears to be essential. We proceeded to deter-
mine whether RAUL is required for IRF7 and IRF3 polyubiquitina-
tion under stress conditions. Primary mouse bone marrow
dendritic cells were isolated (Tseng et al., 2001) and electropo-
rated with a dominant-negative form of RAUL (RAUL-DN) to
suppress RAUL functions and the cells were treated with lipo-
polysaccharide (LPS) to mimic TLR4 activation. As shown in Fig-
ure 2D, LPS readily stimulated IRF7 ubiquitination, whereas
suppression of RAUL by this approach abolished the induced
IRF7 ubiquitination. Likewise, when a stable 293T cell line ectop-
ically expressing toll-like receptor 3 (293T-TLR3), which consti-
tutively express TLR3, was stimulated with poly(I:C) to mimic
TLR3 activation, polyubiquitinated forms of IRF3 were induced,
but silencing RAUL abrogated the effect (Figure 2E). Therefore,
these results suggest that RAUL is also required for polyubiqui-
tination of the much higher stress-induced amounts of IRF7
and IRF3.
To determine whether RAUL is able to directly catalyze the
conjugation of ubiquitination on both proteins, we reconstituted
the ubiquitination of IRF7 and IRF3 in a cell-free system by using
purified glutathione-S-transferase (GST)-IRF7 or GST-IRF3, E1,
UbcH5a (E2), and Ub proteins. RAUL efficiently catalyzed the
conjugation of poly-Ub chains on both IRF7 and IRF3 in cooper-
ation with the E2 enzyme UbcH5a. Omission of any one of these
ingredients or by using an IRF7 N-terminal deletion mutant as
substrate abolished ubiquitination (Figures 2F and 2G). Collec-
tively, these results provide strong evidence that RAUL catalyzes
polyubiquitination on IRF7 and IRF3 both in vitro and in cells
under both physiologically normal and induced stress settings.(E) RAUL is required for ubiquitination of IRF3 after TLR3 activation. 293T-TLR3
with poly(I:C) (25 mg/ml for 9 hr) or MG115 (0.5 mM for 12 hr). Conjugated IRF3 was
anti-Flag.
(F andG) RAUL catalyzes the conjugation of poly-Ub chains on IRF7 and IRF3 in vi
or truncated GST-IRF7 or GST-IRF3 plus E1, UbcH5a (E2), and Ub at 37C for 1 h
with Ub antibody for detection of polyubiquitinated forms of IRF7 and IRF3. Only
compared to 400 nM of target proteins to minimize interference from RAUL auto
(H) Determining IRF7 and IRF3 Ub chain structure by single lysine mutant assay i
mutants, plus E1, E2 (Ubc5a), GST-IRF7, and RAUL were employed in in vitro cel
immunoblotting (bottom).
ITherefore, we conclude that RAUL represents a bona fide
endogenous Ub E3 ligase that directly catalyzes ubiquitination
of both IRF3 and IRF7.
RAUL Catalyzes Lysine 48-Linked Poly-Ub Chains
on IRF7 and IRF3
To determine what type of Ub chain structure was formed on the
IRF7 and IRF3 proteins, first we employed a set of mutants in
which six out of the seven lysine residues (lysine 6, 11, 27,
29, 33, 48, and 63) in the Ub molecule were mutated to
arginine, leaving just one lysine for polymerization. These
recombinant Ub point mutants plus the Ub mutant with all seven
lysines mutated to arginine (KO) were tested in a cell-free Ub
assay to determine which lysine is utilized (Figure 2H, top). As
shown in Figure 2H (bottom) and Figure S2A, RAUL catalyzed
the conjugation of poly-Ub chains on both proteins only with
the Ub mutant retaining a lysine at position 48 (K48), indicating
that RAUL catalyzes lysine 48-linked Ub chains on both proteins
in vitro. We then tested these Ub single lysine mutants plus
a lysine 48 point mutation (K48R) in transfected cells. In accord
with the in vitro cell-free data, IRF7 and IRF3 polyubiquitination
was observed only with Ub mutants containing lysine at position
48 (K48), but not with any mutants where lysine 48 was elimi-
nated (K48R) (Figures S2B–S2D). Therefore, these findings
provide evidence that the poly-Ub chains on IRF7 and IRF3 by
RAUL are linked primarily via lysine 48 of Ub.
RAUL Is Important for Expression of IRF7 and IRF3
as well as Restraining Type I IFN Responses
To determine whether RAUL is a physiologically relevant regu-
lator for IRF7 and IRF3, we generated a plasmid-based RAUL
siRNA. Figure 3A shows that the RAUL-specific siRNA caused
a very effective reduction of RAUL protein compared to a
randomly scrambled negative control siRNA. Furthermore,
silencing RAUL caused a dramatic accumulation of endogenous
IRF7 and IRF3 proteins in 293T, HeLa, and primarymouse spleen
cells (Rag2/ c.c7 TCR transgenic T lymphocyte cells) (Figures
3B and 3C). To eliminate the possibility that the accumulation of
IRF7 and IRF3 here was caused by nonspecific double-stranded
RNA-mediated activation of IFN responses, IRF1 and IRF2 were
included as controls and their amounts were not affected
(Figure 3B), confirming the specificity of the siRNA. RAUL
silencing also led to accumulation of endogenous IRF3 and
IRF7 protein by more than 10-fold in a dose-dependent manner
(Figure 3D) and extended their half-lives by several-fold in the
presence of cycloheximide (CHX) (Figure 3E), indicating a crucial
role for RAUL in negative regulation of the resting forms of both
proteins.cells were transfected with Flag-Ub plasmids and indicated cells were treated
evaluated by immunoprecipitation with anti-IRF3 followed by immunoblot with
tro. Purified GST-RAUL protein was incubated with various combinations ofWT
r. After the ubiquitination reaction, the samples were subjected to immunoblot
a low catalytic concentration of GST-RAUL (20 nM, as an E3 source) was used
ubiquitination (lane 3).
n vitro. Illustration of Ub lysine mutants (top). Purified WT Ub or its single lysine
l-free Ub assays and ubiquitinated forms of the proteins were evaluated by Ub
mmunity 33, 863–877, December 22, 2010 ª2010 Elsevier Inc. 867
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Figure 3. Silencing RAUL Increases IRF7 and IRF3 Expression
(A) Immunoblot of lysates with RAUL-specific antibody from 293T cells transiently expressing siRNA-RAUL or scramble siRNA.
(B and C) Reducing RAUL specifically induces high amounts of endogenous IRF7 and IRF3 proteins in both cell lines and primary cells.
(B) Immunoblot with anti-IRF7 or anti-IRF3 of lysates from cells transiently expressing siRNA-RAUL or scramble siRNA in HeLa or 293T cells.
(C) Isolated primary T lymphocytes from 5-week-old Rag2/ 5c.c7 TCR transgenic knockout mice were activated with pigeon cytochrome C (PCC) and
expanded for 4 days. After activation, more than 90% of the cell population was TCR-specific transgenic T lymphocyte cells, which were then transfected
with siRNA RAUL or scrambled siRNA. Endogenous IRF3 and IRF7 proteins were determined by IRF3 or IRF7 immunoprecipitation followed by immunoblot.
(D) siRNA-mediated reduction of RAUL increases accumulation of both the IRF7 and IRF3 proteins in a dose-dependentmanner. 293T cells were transfectedwith
2-fold increasing amounts of siRNA-RAUL, and endogenous IRF7 or IRF3 protein was determined by IRF7 or IRF3 immunoblot.
(E) Silencing RAUL extends the half-lives of IRF7 and IRF3 proteins. Flag-IRF7 or HA-IRF3 were cotransfected with siRNA-RAUL or scrambled siRNA into 293T
cells, and the protein synthesis inhibitor cyclohexamide (CHX) was added at a concentration of 30 mg/ml at 36 hr for the indicated times. The IRF7 and IRF3
proteins were determined by Flag or HA immunoblot.
(F) Silencing RAUL in 293T-TLR3 cells increases the amount of IRF3 protein. Immunoblot analysis of IRF3 protein from 293T-TLR3 cells transiently expressing
siRNA-RAUL or Myc-RAUL. poly(I:C) was used to stimulate TLR3 activation.
(G) RAUL also regulates a constitutively active form of IRF7. Immunoblot analysis of lysates with IRF7 antibody from 293T cells transiently coexpressing Myc-
RAUL and IRF7S477D and S479D in the presence and absence of MG132.
(H) Enforced RAUL expression augments the Sendai virus-mediated loss of IRF7 protein. Myc-RAUL and Flag-IRF7 plasmids as indicated were transfected into
293T cells infected with Sendai virus (16 hr) with or without treatment with MG132. IRF7 protein was evaluated by immunoblot with a Flag antibody.
Immunity
RAUL Regulates Type I IFN via IRF7 and IRF3To address whether RAUL also regulates the active forms of
both proteins, we examined how silencing of RAUL affected
the amounts of IRF7 and IRF3 under stress conditions. First, in
293T-TLR3 cells treated with poly(I:C) to activate IRF3, the
reduction of RAUL by siRNA resulted in an accumulation of the
endogenous active form of IRF3 protein over the control (Fig-868 Immunity 33, 863–877, December 22, 2010 ª2010 Elsevier Inc.ure 3F). Similarly, coexpression of RAUL with a constitutively
active form of IRF7 (S477D and S479D) (Lin et al., 2000) in
293T cells led to the loss of these proteins, which was rescued
by treatment with the proteasome inhibitor MG132 (Figure 3G).
In Sendai virus-infected cells, coexpression of RAUL with IRF7
caused a further loss of the expected to be fully active form of
Immunity
RAUL Regulates Type I IFN via IRF7 and IRF3IRF7, which could be prevented by adding MG132 (Figure 3H).
These results demonstrate a role for RAUL in the negative regu-
lation of both TLR3-activated IRF3 and Sendai virus-activated
forms of IRF7 proteins. Collectively, these data indicate that
RAUL downregulates both resting and active forms of both
proteins.
We next investigated whether suppression of RAUL by either
siRNA or dominant-negative approaches would translate into
an increase of type I IFN production under resting and stress
conditions. Indeed, depletion of RAUL by siRNA strongly acti-
vated IFN-a1 and IFN-b reporter activities, and Sendai virus
infection further increased their activities (Figure 4A). An identical
pattern was also observed in poly(I:C)-stimulated 293T-TLR3
cells (Figure 4B). Likewise, silencing RAUL in DC 2.4 cells
augmented both basal and LPS-stimulated IFN-a1 mRNA (Fig-
ure 4C). These siRNA and dominant-negative studies provide
confirmation of the importance of RAUL in regulating the expres-
sion of type I IFN.
We also examined whether ectopic expression of RAULwould
affect IRF7- and IRF3-dependent type I IFN activation. Coex-
pression of RAUL together with IRF7 or IRF3 in 293T cells
completely abolished the IRF7- and IRF3-mediated type I IFN
reporter gene activities in both the absence and presence of
Sendai virus or of poly(I:C) or LPS (Figures 4D–4F). These results
imply that RAUL exerts a powerful restrictive function on IRF7
and IRF3-dependent type I IFN responses via TLR signaling in
a variety of pathogenic settings. Evidently, with the IRF7 and
IRF3 proteins degraded, the cells’ ability to launch a type I IFN
response was eliminated. As indicated in Figure 4G, coexpres-
sion of RAUL with IRF7 or IRF3 completely inhibited their
induction of endogenous IFN-a and IFN-b mRNA measured by
real-time reverse transcription-polymerase chain reaction (RT-
PCR). Notably, ectopic expression of RAUL alone decreased
IFN-a and IFN-b to 20%–50% of the basal amounts in mock-
treated cells as well. The results for IFN-a and IFN-b mRNA
measurements were essentially the same as for IFN-promoter
driven luciferase (IFN-LUC) reporter assays for all of the above
experiments with poly(I:C) and LPS induction (not shown, except
for Figure 4C).
Collectively, these data demonstrate that RAUL regulates the
stability and amount of both the inactive and activated forms of
IRF7 and IRF3 proteins and points to a critical role for RAUL
both in maintaining proper low amounts of type I IFN in normal
conditions, as well as for restraining the magnitude of induced
antiviral responses. A previous study demonstrated that Pin1
also indirectly targets IRF3 for destabilization through polyubi-
quitination and suggested that additional posttranslational
mechanisms may be involved (Saitoh et al., 2006). RAUL could
represent one of them, although our further investigation has
revealed that the E3 activity of RAUL toward IRF7 and IRF3 is
independent of Pin1 activity and vice versa (data not shown).
The Role of RAUL in Antiviral Innate Immunity
To address the role of RAUL in the innate antiviral response, we
infected mouse embryonic fibroblasts (MEFs) with KSHV and
monitored alterations in overall viral load in the infected cells
via a real-time PCR-based method, which is able to quantify
the copy number of KSHV genomes (Figure 5A). The amount of
KSHV DNA generated in these the infected cells was measuredIas 51 copies per 100 ng of cell DNA. Ectopic expression of
RAUL, which should suppress IRF3- and IRF7-mediated type I
IFN production, boosted the production of KSHV by nearly
5-fold (240 versus 51 copies). In contrast, in the cells expressing
dominant-negative or siRNA RAUL, the viral copy number was
instead decreased by 68%–77% (12 and 16 versus 51 copies)
(Figure 5B). A parallel type I IFN assay by real-time PCR
confirmed a reduction of type I IFN mRNA production subse-
quent to ectopic expression of RAUL and an increase after
expression of siRNA RAUL (Figure 5C).
To test the generality of this effect, we examined whether the
expression of RAUL also affects the replication of Sendai virus in
infected MEFs. A similar pattern was obtained: Sendai virus
infection readily induced IFN-b production, while concurrent
ectopic expression of RAUL abolished it (Figure 5D, lane 8
versus 5). As a result, the virus proliferated more efficiently (Fig-
ure 5E, lane 8 versus 5). In contrast, suppression of RAUL by
dominant-negative or siRNA boosted IFN-b production (Fig-
ure 5D, lanes 6 and 7 versus 5) and caused a reduction of viral
proliferation (Figure 5E, lanes 6 and 7 versus 5). We also exam-
ined whether RAUL affected KSHV DNA concentration in latently
infected primary effusion lymphoma (PEL) BCBL1 cell lines
selected to stably express either RAUL or siRNA-RAUL. Ectopic
expression of RAUL increased the KSHV viral load over the
control by 716% (9837 versus 1373 copies), and depletion of
RAUL by siRNA reduced the viral DNA yield by 73% (364 versus
1373 copies) (Figure 5F).
Previous studies have suggested that two other Ub E3 ligases,
RBCK1 and Ro52, also regulate IRF3 ubiquitination and type I
IFN, although it is unknown whether the IRF3 ubiquitination
mediated by these E3s is direct or whether it occurs with the
endogenous forms of these proteins. Therefore, a question arose
about their contributions relative to RAUL to IRF3 ubiquitination,
to IFN-b production, and more importantly to viral replication. To
compare their E3 activity toward catalyzing IRF3 conjugation, we
first silenced all three E3s individually via RNA interference in
293T-TLR3 cells and examined the conjugation of endogenous
IRF3 in response to poly(I:C). Figures 5G and 5H depict the effi-
cacy of siRNA-RBCK1 and siRNA-Ro52 in silencing RBCK1 and
Ro52 genes in 293T cells. As shown in Figure 5I, this resulted in
different degrees of reduction in IRF3 conjugation with the
largest reduction being observed after silencing RAUL. Next,
we evaluated the effects of these siRNAs on IFN-b production.
Silencing RBCK1 or RAUL or Ro52 in Sendai virus-infected
293T cells caused an increase of IFN-b mRNA production by
3-, 12-, and 4-fold, respectively, with lower effects on mock-
infected cells (Figure 5J). Again, silencing RAUL produced the
greatest increase both with and without Sendai virus infection.
Last, we compared the impact of silencing these E3s on Sendai
virus replication. Compared to the control, depletion of RBCK1
or RAUL or Ro52 led to a reduction in Sendai virus yield by
24%, 76%, and 56%, respectively (Figure 5K). Collectively,
these data suggest that all three E3s play some role in the
negative regulation of IFN-b production through directly or indi-
rectly catalyzing proteolytic IRF3 ubiquitination. Nevertheless,
RAUL evidently has by far the more predominant role, possibly
because of its unique capability to directly ubiquitinate both
IRF3 and IRF7. Overall, our findings offer biological evidence
that RAUL, through negatively controlling IRF7 and IRF3 proteinmmunity 33, 863–877, December 22, 2010 ª2010 Elsevier Inc. 869
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Figure 4. RAUL Negatively Regulates IRF7- and IRF3-Mediated Type 1 IFN Production
(A–C) Suppression of RAUL by siRNA or dominant-negative augments type 1 IFN activity.
(A) Luciferase assay of 293T cells transiently expressing siRNA-RAUL together with IFN-a1 or IFN-b luciferase reporter plasmids. The cells were infected with
Sendai virus for 16 hr before harvest. The basal IFN-a and IFN-b activities were arbitrarily set to 1.0.
(B) Luciferase assay of IFN-b promoter activity from 293T-TLR3 cells transiently expressing dominant-negative RAUL in the presence or absence of poly(I:C)
(25 mg/ml) for 9 hr to activate IRF3.
(C) Silencing of RAUL increases IFN-a1 mRNA in dendritic cells. DC 2.4 cells were electroporated with siRNA-RAUL or scrambled siRNA in the presence or
absence of LPS. Total RNA was isolated and subjected to SYBR green real-time RT-PCR with primers for IFN-a1.
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RAUL Regulates Type I IFN via IRF7 and IRF3stability, strongly limits the magnitude of the innate antiviral
response.
KSHV Recruits and Enhances the Function of RAUL
Both IRF7 and RAUL are binding partners for KSHV RTA, and we
also observed that RTA can enhance the ability of RAUL to
degrade both IRF7 and IRF3 in a cotransfection system (Fig-
ure 6A). These observations prompted us to investigate the
possibility that RTA utilizes or modifies the RAUL regulatory
mechanism for type I IFN to augment its own direct effects on
blocking the antiviral response. We first confirmed the interac-
tion between RTA and RAUL in vitro by a cell-free GST pull-
down assay (Figure 6B). By using specific antibodies to both
proteins, we also detected this binding with the endogenous
protein in KSHV-infected BCBL1 cells, especially after TPA treat-
ment, which induced the expression of RTA (Figure 6C). To
address the functional consequences of this binding, we exam-
ined whether RTA affected the stabilization of RAUL in both
TRExRTA BCBL1 and standard BCBL1 PEL cell lines. Induction
of RTA expression by either doxycycline (Dox) or TPA, respec-
tively, substantially increased the steady-state amount of endog-
enous RAUL (Figures 6D and 6E), which in turn decreased the
abundance of IRF3 and IRF7 (Figure 6E), but it had no effect
on the amounts of IRF1 (Figure 6D), whose stability is also regu-
lated independently by a ubiquitination-mediated pathway
(Nakagawa and Yokosawa, 2000). To address whether this
change in the abundance of RAUL might involve posttransla-
tional modification, we coexpressed RTA with RAUL in 293T
cells. RTA dramatically reduced the degree of RAUL self-ubiqui-
tination, with a concomitant increase in unconjugated RAUL
(Figure 6F), implying that RTA-mediated deubiquitination of
RAUL rescues it from self-induced protein degradation.
KSHV RTA Mediates RAUL Deubiquitination via Usp7
RAUL, as an E3 ligase, mediates the ubiquitination of not only its
substrates but also itself (self-ubiquitination), leading to proteol-
ysis of RAUL. We set out to investigate the mechanism under-
lying KSHV RTA-mediated RAUL deubiquitination and found
that RTA promotes RAUL deubiquitination through a deubiquiti-
nating enzyme Usp7 (formerly known as HAUSP) (Everett et al.,
1997), which is best known for stabilizing p53 through deubiqui-
tination (Li et al., 2002).
First, we investigated whether Usp7 can directly interact
with RAUL. By using specific Usp7 and RAUL antibodies, we
detected an interaction between endogenous RAUL and endog-
enous Usp7 proteins in BCBL1 cells (Figure 7A). To test the
specific deubiquitination activity of Usp7 on RAUL, we examined
whether Usp7 regulated RAUL ubiquitination in transfected cells.
As shown in Figure 7B, a large amount of conjugated RAUL was
detected in cells transfected with RAUL and HA-Ub; however,
RAUL ubiquitination was completely abolished by Usp7 expres-
sion, and the Usp7 catalytically inactive mutant Usp7-cs failed to(D–F) Enforced RAUL expression abolishes IRF7- and IRF3-mediated type I IFN i
were cotransfected with IFN-a1 or IFN-b luciferase reporters, IRF7 or IRF3, and RA
by LPS (100 ng/ml, for 9 hr) or poly(I:C). IFN promoter activation was determine
(G) RAUL inhibits IRF7- or IRF3-mediated type I IFN mRNA production. 293T cel
RNA was isolated and subjected to SYBR green real-time RT-PCR with primers
output.
Ideubiquitinate RAUL. We then examined whether Usp7 can
directly deubiquitinate RAUL in a purified protein system. A poly-
ubiquitinated form of RAUL was generated in an in vitro
Ub-conjugation system in the presence of E1, E2 (UbcH5a),
and Ub. The resulting purified product was then subjected to
in vitro deubiquitination in the presence of the WT or mutant
Usp7 proteins purified from insect cells (Everett et al., 1997).
RAUL alone generated high-molecular-weight moieties in the
presence of E1, E2, and Ub, but including the Usp7 protein effi-
ciently eliminated the poly-Ub moieties attached to RAUL,
whereas its catalytically inactive point mutant Usp7-cswas func-
tionally defective in deubiquitinating RAUL (Figure 7C, lanes 2
and 3). These data collectively indicate that Usp7 can deubiqui-
tinate RAUL both inside cultured cells and in cell-free systems.
We then investigated the functional consequences of the
deubiquitination of RAUL. To determine the effect of Usp7 on
RAUL protein, we examined the endogenous RAUL protein in
Usp7 WT and silenced cells. Ablation of Usp7 gave rise to a
decrease in RAUL protein and a concomitant increase in its
substrate IRF3 (Figure 7D). This result indicates that Usp7
expression plays an important role in maintaining the stability
of RAUL and presumably also of its cellular functions. To assess
the effect of Usp7 toward the E3 activity of RAUL, we purified
RAUL protein by immunoprecipitation from cells that either
expressed RAUL alone or coexpressed RAUL together with
Usp7, and incubated them in vitro with purified GST-IRF3, E1,
UbcH5a, and Ub to evaluate the activity of RAUL toward IRF3.
Inclusion of RAUL from RAUL + Usp7-expressing cells resulted
in a large increase of the ubiquitinated forms of IRF3 compared
to in the absence of Usp7 (Figure 7E). This result indicates that
Usp7 augments the E3 enzymatic activity of RAUL.
We next investigated whether KSHV RTA mediates RAUL
deubiquitination through Usp7. To determine whether RTA
assists in recruiting Usp7 to RAUL, we used doxycyclin (DOX)
to induce RTA expression in TREx-BCBL1 cells. By using
specific antibodies, an increase in the association of endoge-
nous Usp7 with RAUL was observed in the presence of RTA
(Figure 7F), suggesting that RTA recruits Usp7 to the RAUL
protein to form RTA-Usp7-RAUL complexes and that this induc-
ible Usp7-RAUL association can be enhanced upon RTA activa-
tion. To determine whether Usp7 is required for RTA-mediated
RAUL deubiquitination, we transfected RTA into both parental
colon cancer HCT116 Usp7+/+ cells and into a derived cell line
with the Usp7 gene homozygously disrupted (HCT116 Usp7/).
As shown in Figure 7G, ectopic expression of RTA in WT Usp7
cells resulted in deubiquitination of endogenous RAUL, whereas
added RTA failed to deubiquitinate RAUL in Usp7 null cells
(Usp7/). Therefore, this result provides strong evidence that
the deubiquitination and stabilization of RAUL by RTA occur
via Usp7.
Finally, we sought to explore the functional consequence
of RTA-promoted, Usp7-mediated RAUL deubiquitination bynduction under Sendai virus or LPS or poly(I:C) stimulation. The indicated cells
UL and the indicated cells were infected with Sendai virus (16 hr) or stimulated
d by luciferase assay.
ls were cotransfected with IRF7, IRF3, and RAUL plasmids as indicated. Total
for IFN-a1, IFNa-1-12, and IFN-b, respectively, to assess type 1 IFN mRNA
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Figure 6. RTA Recruits and Enhances RAUL
(A) RTA enhances the ability of RAUL to degrade IRF7 and IRF3. 293T cells were cotransfected with RTA, Myc-RAUL, or Myc-RAUL-DN, IRF7, and IRF3 as indi-
cated and the amounts of IRF7 and IRF3 proteins were detected by IRF7 or IRF3 immunoblot.
(B and C) RTA binds to RAUL in vitro and in vivo.
(B) A GST-pull down assay was carried out with 35S-labeled in vitro translated RAUL and GST-RTA proteins.
(C) Cell lysates from BCBL1 PEL cells were immunoprecipitated with anti-RTA followed by RAUL immunoblot to detect endogenous RTA-RAUL interaction with
TPA.
(D and E) Induction of RTA stabilizes RAUL protein.
(D) TREx BCBL1 cells treated with doxycycline (Dox) for the indicated times to induce RTA expression, and RAUL, IRF3, IRF1, and RTA proteins were monitored
by immunoblot with the indicated antibodies.
(E) BCBL1 PEL cells were treated with TPA to induce RTA expression and cytoplasmic and nuclear fractions were isolated. The RAUL, IRF7, IRF3, and RTA
proteins were evaluated by immunoblot with the indicated antibodies.
(F) RTA mediates RAUL deubiquitination. RTA andMyc-RAUL plasmids were cotransfected into 293T cells and ubiquitinated forms of RAUL were determined by
immunoblot with anti-Myc. To show both ubiquitinated and nonubiquitinated forms of RAUL, a short-exposure film was included (bottom).
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RAUL Regulates Type I IFN via IRF7 and IRF3coexpressing RTA, RAUL, and IRF7 in 293T cells. As before,
expression of RTA cooperated with RAUL to enhance degrada-
tion of the IRF7 protein (Figure 7H); however, concurrentlyFigure 5. RAUL Regulates the IFN-Mediated Antiviral Response
(A) A SYBR real-time PCR-based quantitative approach for determining KSHV vir
the comparative Ct method. The viral load value, normalized to reference (b-act
expressed as copy number per 100 ng of infected cell genomic DNA.
(B–E) Role of RAUL in KSHV and Sendai virus-infected mouse embryonic fibroblas
DN, or siRNA-RAUL and the cells were infected with KSHV or Sendai virus for t
(KSHV) per 100 ng of genomic DNA or relative viral RNA load (Sendai virus) (B and
(F) Role of RAUL in KSHV-infected BCBL1 cells. Lysates from BCBL1-derived ce
viral DNA copy number per 100 ng genomic DNA.
(G and H) Comparison of the contribution of RBCK1, RAUL, and Ro52 to endoge
specific antibody from 293T cells transiently expressing siRNA-RBCK1 or siRNA
(I) Comparison of siRNA silencing to reduce polyubiquitination of IRF3 in activated
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The conjugation of endogenous IRF3 was detected by immunoprecipitation with
(J and K) Relative roles of RBCK1, RAUL, and Ro52 in viral replication. 293T cells w
with Sendai virus for the indicated times. The cell lysates were assayed for IFN
RT-PCR (K).
Isilencing Usp7 severely impaired this effect. Likewise, RTA
increased the ability of RAUL to suppress IRF3-mediated IFN-b
reporter activation in 293T-TLR3 cells, whereas RTA failed toal load. The standard curve was constructed with KSHV RAP DNA as target by
in), is given by 2 –DDCt in the Applied Biosystems 7500 Real Time PCR system
t cells (MEFs). MEF cells were electroporated withWT RAUL, dominant RAUL-
he indicated times. The cell lysates were assayed for viral DNA copy number
E) as well as for type 1 IFN mRNA production by real-time RT-PCR (C and D).
ll lines stably expressing either RAUL or siRNA-RAUL were assayed for KSHV
nous IRF3 ubiquitination. Immunoblot of lysates with RBCK1- (G) or Ro52- (H)
-Ro52 or scramble siRNA.
cells. 293T-TLR3 cells were transfected with siRNA against RBCK1 or RAUL or
ly-Ub conjugation of IRF3 in the presence of the proteasome inhibitor MG115.
IRF3 antibody and immunoblot with Flag antibody.
ere transfected with siRNA against RBCK1 or RAUL or Ro52, and then infected
-b mRNA production (J) and for viral RNA load of Sendai virus by real-time
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Figure 7. RTA Mediates RAUL Deubiquitination through Usp7
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immunoblot to detect bound protein.
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RAUL Regulates Type I IFN via IRF7 and IRF3do so in the same cells after Usp7 was silenced by shRNA (Fig-
ure 7I). The Usp7 shRNA also led to reduced inhibition of IRF3-
mediated IFN-LUC activity by both RAUL and RTA alone. These
results demonstrate that RTA augments RAUL’s activity toward
its substrates IRF7 and IRF3 through Usp7 and reinforces the
notion that Usp7 acts as a positive regulator for RAUL.
Taken together, these findings reveal an important posttransla-
tional regulatory mechanism for RAUL, in which the DUB enzyme
Usp7 positively regulates RAUL by preventing it from proteolytic
self-ubiquitination and that KSHV RTA exploits this mechanism
while amplifying RAUL activity to mute antiviral responses.
DISCUSSION
In this report, we have identified an important negative regulatory
mechanism acting on the type I IFN pathway that is probably
required for both appropriate cellular homeostasis and for reset-
ting the basal state after induction of antiviral innate immunity.
This mechanism relies on the E3 ligase activity of RAUL, which
exerts its inhibitory action on type I IFN by directly catalyzing
lysine 48-linked polyubiquitination on both IRF7 and IRF3, the
two most crucial transcriptional factors for mounting type I IFN
responses. In all circumstances tested, increased or decreased
amounts of RAUL negatively correlated with either strong nega-
tive or positive effects, respectively, on endogenous type I IFN
production.
The implications of this mechanism are 3-fold. (1) In physiolog-
ical conditions, it helps to keep type I IFN production at proper
low basal amounts through targeting IRF7 and IRF3 ubiquitina-
tion and degradation. (2) Under stress conditions, in which type
I IFN amounts rise dramatically, it may act as a ‘‘speed brake’’
to prevent detrimental overproduction. (3) Given its crucial role
in type I IFN regulation, control of RAUL function may also
become a battleground in the war between viruses and the host
during infection. High interferon doses administered to patients
can cause toxic effects, indicating a need for timely and spatially
coordinated downregulation mechanisms for type I IFN and for
effective combat against infectious agents. We propose that
RAUL, operating upstream of IRF7 and IRF3, is a key factor for
maintaining appropriate cellular homeostasis and for antiviral
innate immunity through controlling both the basal amount and
intensity of induced type I IFN responses. We speculate that
some of the other previously reported viral and cellular proteins
that influence the ubiquitination status of both proteins might
also exert their actions through the Ub E3 ligase RAUL.(D) Usp7 upregulates RAUL protein amounts. Colon cancer cell lines HCT116 Usp
uate both RAUL and its target substrate IRF3.
(E) Usp7 enhances the E3 activity of RAUL toward IRF3 in vitro. Immunopre
RAUL+Usp7-expressing 293T cells were incubated with its substrate GST-IRF
determined by Ub immunoblot.
(F) RTA increases the recruitment of Usp7 to RAUL complexes. TRExBCBL1 cells
enous RTA-Usp7-RAUL interaction was evaluated by immunoblot with the indica
(G) RTA promotes RAUL deubiquitination. HCT116 (Usp7+/+ or Usp7/) cells we
ubiquitination was determined by Ub immunoblotting. Unconjugated RAUL and
(H) RTA enhances the ability of RAUL to degrade IRF7 via Usp7. 293T cells were
IRF7 protein amounts were evaluated by IRF7 immunoblotting.
(I) RTA and RAUL cooperate in suppressing IRF3-mediated IFN-b reporter activi
RAUL, RTA, shRNA-Usp7, and IFN-b-LUC plasmids and the cells were treated
activity in the cells that were pretreated shRNA-RAUL or scrambled IFN-b activa
IIRF7 and IRF3 comply with all four of the criteria that should
be met by specific HECT domain E3 ligase substrates (You
et al., 2003). (1) They both bind to the N-terminal substrate
binding domain of RAUL. (2) Purified RAUL specifically cata-
lyzes the conjugation of ubiquitin on IRF7 and IRF3 in vitro. (3)
Their protein amounts are reduced by coexpression with
RAUL, but not by its catalytically inactive mutant, and this desta-
bilization is proteasome dependent. (4) Depletion of RAUL
increases the stability and hence overall amount of both
proteins.
Our investigation into the role of KSHV RTA in RAUL signaling
led us to uncover a critical role for deubiquitination in the regula-
tion of RAUL function. Ubiquitination is a dynamic process that
involves constantly adding and removing Ub moieties from the
substrate. Self-ubiquitination plays an important role in the regu-
lation of RING finger domain ligases TRAF2, TRAF3, and TRAF6,
and deubiquitination-mediated protein stabilization has
emerged recently as an accompanying regulatory step (Chom-
varin et al., 2004; Friedman et al., 2008; Kayagaki et al., 2007;
Wang et al., 2001; Yang et al., 2006). HECT domain Ub ligases,
once thought to be constitutively active and to recognize their
substrates independently of their posttranslational modification,
are also subjected to posttranslational regulation (Gao et al.,
2004; Wiesner et al., 2007). It appears that, on one hand,
RAUL is capable of catalyzing polyubiquitination constitutively,
an ability that is required for regulating the resting forms of the
IRF7 and IRF3 proteins; whereas on the other hand, RAUL
activity can also itself be regulated through posttranslational
mechanisms under pathogenic settings, which is important for
regulating the active forms of both IRF proteins.
Several recent studies have indicated that some Ub E3 ligases
are physically associated with DUBs that directly reverse self-
ubiquitination of the ligase, thus regulating its activity. However,
only one HECT domain ligase, Rsp5, has been previously shown
to be regulated by a DUB Ubp2, and no effect on its E3 ligase
activity was observed (Kee and Huibregtse, 2007; Shembade
et al., 2010). Our findings suggest that RAUL can be rescued
from undergoing self-ubiquitination-mediated degradation by
Usp7 via direct deubiquitination, which represents an important
posttranslational regulatory mechanism for RAUL. Its activity is
increased through deceleration of the self-induced degradation
and decreased via acceleration of the degradation. Thus it
appears that Usp7 is capable of cleaving Ub chains with both
lysine 48- and 63-linkage from both RING finger and HECT
domain E3 Ub ligases.7+/+ or Usp7/ cells were immunblotted with the indicated antibodies to eval-
cipitated purified RAUL protein from either RAUL-expressing 293T cells or
3, plus E1, UbcH5a, and Ub in vitro at 37C for 1 hr. Conjugated IRF3 was
were treated with Doxycyclin (Dox) for 12 hr to activate RTA expression. Endog-
ted antibodies.
re electroporated with the indicated amounts of RTA plasmid and RAUL self-
RTA were measured by RAUL or RTA immunoblotting.
cotransfected with IRF7, Myc-RAUL, RTA, and shRNA-Usp7 as indicated, and
ty. 293T-TLR3 cells were transfected with the indicated combinations of IRF3,
with poly(I:C) for 9 hr to mimic TLR3 activation. IRF3-mediated IFN-b reporter
tion was determined by luciferase assays.
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RAUL Regulates Type I IFN via IRF7 and IRF3Much of our knowledge with regard to immunity comes from
understanding how cells deal with viral infection, from smallpox
to human immunodeficiency virus (HIV). The observation that
KSHV RTA activates RAUL activity through Usp7 embodies
a striking example of virus-mediated manipulation of a cellular
ubiquitination pathway. This is reminiscent of another HECT
domain Ub E3 ligase, E6AP, which mediates the ubiquitination
of p53 in cells that express the human papillomavirus (HPV) E6
oncoprotein. Evidently Sendai virus is also able to take advan-
tage of RAUL signaling during infection, suggesting that this
scheme may be generally relevant to other viral infections. A
common strategy adopted by viruses to counteract innate
immunity is to mimic or seize existing cellular pathways and to
utilize them in their favor (McCormick and Ganem, 2005; Scheff-
ner et al., 1990). Therefore exploring these ‘‘commandeered
pathways’’ unveils not only the pathogenesis involved but also
uncharted cellular pathways.
EXPERIMENTAL PROCEDURES
Reagents
pCMV-MyC-RAUL (WT, 1083 amino acids) and the pCMV-MyC-RAUL HECT
domain point mutant (C1051A), as well as pET3a-RAULWT, pET3a-RAUL-
ND (1–655), and pET3a-RAUL-CD (655–1083) for in vitro translation were
provided by C.M. Pickart (Bloomberg School of Hygiene, Johns Hopkins
University). RAULD132 was provided M. Wang. pIRF7A (1–503), pFLAG-
IRF7A (1–503), pGST-IRF7 (1–503), and pGST-IRF7 (255–503) and reporter
plasmids encoding firefly luciferase (LUC) under the control of human
IFN-a1 (–140 to +9) and IFN-b (280 to +20) promoter elements were provided
by Y. Yuan (Zhu et al., 2002). pIRF7DN (aa 1–12 and 103–503) was provided
by T. Maniatis (Wathelet et al., 1998). pIRF7C was provided by J.S. Pagano
(University of North Carolina) (Zhang and Pagano, 1997). IRF7S477D and
S479D was provided by J. Hiscott. pHA-Ub was provided by K. Watanabe
(Sasaki et al., 2002). pFLAG-Ub, pHA-IRF3, pHA-IRF3 (1–128), pHA-IRF3
(1–374), pGST-IRF3 (58–427), and pGST-IRF3 (175–427) were provided by
T. Fuita (Wathelet et al., 1998). pGST-IRF3 was provided byM.E. Hardy (Veter-
inary Molecular Biology Laboratory) (Graff et al., 2002), 293T-TLR3 cell lines
was provided by K. Fitzgerald (Fitzgerald et al., 2003), and HCT116 Usp7+/+
and Usp7/ cell lines were provided by B. Vogelstein (Cummins et al.,
2004). Purified Usp7 protein was provided by R. Everett (Everett et al.,
1997); pcDNA3-Pin1 was provided by A. Ryo (Saitoh et al., 2006); and pSR-
Pin1 (siRNA-Pin1), pSR-Rli (control siRNA), and pEFHA-IRF3S339A were
provided by S. Yamaoka (Saitoh et al., 2006). Rag2 / 5c.c7 TCR transgenic
cells were provided by Y. Zheng and J.D. Powell (Zheng et al., 2007).
Monoclonal antibodies against b-actin, ubiquitin, FLAG, HA, and Myc-
epitopes were purchased from Sigma. Rabbit polyclonal antibody against
GST, Usp7, Ro52, RBCK1, IRF7, and IRF3 were purchased from Santa
Cruz. Control nonimmune antibodies are indicated as IgG. RAUL antibody
was generated in rabbits by using a peptide corresponding to the near
N-terminal sequence of RAUL (Y-KTRPKVSLGGASRKEEK-SC). shRNA-Usp7
was provided by R. Everett.
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